Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.86 |
| ▸ | F2 | P00734 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177790 | 0.93 | F10 (1.00) | F10KCNH2F2 | |
| SCHEMBL14345360 | 0.92 | F10 (1.00) | F10KCNH2F2 | |
| SCHEMBL10063542 | 0.91 | F10 (0.88) | F10KCNH2F2 | |
| SCHEMBL13038369 | 0.90 | F10 (0.88) | F10KCNH2F2 | |
| SCHEMBL12132919 | 0.89 | F10 (0.85) | F10KCNH2F2 | |
| SCHEMBL10181142 | 0.89 | F10 (0.85) | F10KCNH2F2 | |
| SCHEMBL10146279 | 0.89 | F10 (1.00) | F10KCNH2F2 | |
| SCHEMBL13038370 | 0.88 | F10 (0.79) | F10KCNH2F2 | |
| Betrixaban SCHEMBL158591 | 0.87 | F10 (1.00) | F10KCNH2F2 | |
| SCHEMBL799533 | 0.87 | F10 (0.86) | F10KCNH2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946269-B2 | Crystalline forms of a factor Xa inhibitor | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20120071519-A1 | CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR | ALEXION PHARMACEUTICALS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120046230-A1 | Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor | MILLENNIUM PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20100298284-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-7727981-B2 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090131411-A1 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | MILLENNIUM PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131411-A1 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | F12, F2, PIGS | F10 19/4885KCNH2 2996/4885F2 2/4885 |
| US-20120071519-A1 | CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR | F12, F9, F11 | F10 5/4885KCNH2 2595/4885F2 8/4885 |
| US-20100298284-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | F10 13/4885KCNH2 1032/4885F2 5/4885 |
| US-20120046230-A1 | Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor | SERPINC1, F2, TFPI | F10 6/4885KCNH2 1976/4885F2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.